ATEA AT-03A-017
99 years and younger
All genders
Phase 3 study with screening, treatment, follow-up and extended follow up periods. Participants enrolled for up to 60 days. compare the effects, good or bad, of bemnifosbuvir versus placebo, on patients with mild to moderate COVID-19 who are not hospitalized. Participants will have blood tests, influenza tests, covid tests, physicals